BEVERLY HILLS, Calif., August 21, 2018 (Newswire.com) - Skinuva is a revolutionary new scar cream that is the first to use highly selective growth factors in its unique formulation. It is arguably the most advanced scar cream formulated, where clinical studies have shown that it performed two times better than regular silicone cream.
We are glad to announce that our recent head-to-head double-blinded, randomized multicenter study, “Safety and Efficacy of a Scar Cream Consisting of Highly Selective Growth Factors Within a Silicone Cream Matrix: A Double-Blinded, Randomized, Multicenter Study,” comparing Skinuva™ Scar to silicone cream is now in press in Aesthetic Surgery Journal.
The Aesthetic Surgery Journal (ASJ), is an international peer-reviewed journal that focuses on scientific developments and clinical techniques in the fields of aesthetic surgery. ASJ works towards advancing the science, art, and safe practices of aesthetic surgery and cosmetic medicine through original and peer-reviewed research, evidence-based clinical studies, and research articles.
Some of the highlights in Skinuva’s performance are:
Softens and flattens the appearance of scars
Reduces the appearance of redness and discoloration
Relieves itch and discomfort associated with dryness
Sunscreen may be worn over
Gentle for all skin types
No dyes, oils or parabens
In our double-blind, randomized, multi-center comparison study, our patients saw a two-fold improvement in the appearance of their scars when using Skinuva over silicone cream. Out of the 45 patients participating in the study, 10% dropped out because they saw such a noticeable difference inside of their scars that Skinuva was being used on, and preferred to use Skinuva on both sides of the scars that were being tested. On average, there was a 73% improvement in scars that were treated with Skinuva.
Here are some additional updates on Skinuva:
● We have also begun evaluating gene expression (mRNA) in our scars. We're seeing a significant difference in the Collagen Type I and III ratio and fibroblastic response, such the skin we biopsied from those that had received Skinuva™ Scar had gene expression closer to a fetal scar, i.e., low Collagen Type I/III ratio when compared to silicone cream or no treatment. This is data that we've never seen before in scar analysis, and we're very excited to share this news.
● Skinuva™ Scar is the first and only scar cream that uses selective growth factors to help improve the appearance of scars.
Skinuva is currently available to doctors. If you would like to place an order, please visit www.skinuva.com to learn more. Patients wishing to purchase the product can contact us to find a doctor near them who sells Skinuva.
Source: Skinuva Scar